PLEASANTON, Calif., Sept. 20, 2011 /PRNewswire/ — Thoratec
Corporation (NASDAQ:
THOR), a world leader in device-based mechanical circulatory
support therapies to save, support and restore failing hearts, said
today it will be participating in the Lazard Capital Markets 3rd
Annual Circulatory Assist Device Day on Thursday, September 22.
Taylor Harris, Senior Director of Investor Relations and
Business Development, will provide an update on the company,
beginning at 8:30 a.m., Eastern Daylight Time (5:30 a.m., Pacific
Daylight Time). The presentation will be available through the
conference web site at http://www.wsw.com/webcast/lz12/,
or on the company’s web site at http://www.thoratec.com.
Thoratec is a world leader in therapies to address
advanced-stage heart failure. The company’s products include the
HeartMate® LVAS (Left Ventricular Assist System) and
Thoratec® VAD (Ventricular Assist Device) with more than 18,000
devices implanted in patients suffering from heart failure.
Thoratec also manufactures and distributes the CentriMag® and
PediMag® / PediVAS® product lines. Thoratec is
headquartered in Pleasanton, California. For more information,
visit the company’s website at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate, HeartMate II and GoGear
are registered trademarks of Thoratec Corporation. CentriMag and
PediMag are registered trademarks of Thoratec LLC, and PediVAS is a
registered trademark of Thoratec Switzerland GmbH.
‘/>”/>
SOURCE
